JPMorgan raised the firm’s price target on Replimune (REPL) to $19 from $16 and keeps an Overweight rating on the shares. The firm continues to see a high probability of approval for RP1 plus nivolumab in anti-PD1 failed melanoma next week. To reflect “encouraging” physician feedback, the analyst increased the firm’s U.S. peak sales of RP1 to~$700M from $600M. JPMorgan sees the shares rallying to the mid-teens range on approval.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Buy Recommendation for Replimune Group’s RP1 + Opdivo: Promising Efficacy and Favorable FDA Review
- Replimune Group’s Promising Future: Buy Rating Backed by Strategic Launch Plans and Positive Clinical Data
- Optimistic Buy Rating for Replimune Group: Strategic Positioning and Growth Potential Highlighted by TUDRIQEV’s Market Readiness and Expansion Opportunities
- Replimune Group Hosts Investor Day for Updates
- Replimune initiated with an Overweight at Cantor Fitzgerald